This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Gyldmark M, Aultman R, Siebert U, Sabate E.Cost-effectiveness of first-line combination treatment with bevacizumab plus FOLFIRI versus FOLFIRI in patients with metastatic colorectal cancer: a UK perspective. 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research: 49 abstr. PCN69, 16 May 2009. Available from: URL: http://www3.interscience.wiley.com
Holmberg C, Aultman R, Siebert U, Sabate E, Gyldmark M.Modelling the cost effectiveness of first-line combination treatment with bevacizumab plus irinotecan and infusional fluoropyrimidines versus irinotecan and infusional fluoropyrimidines in metastatic colorectal cancer patients in Sweden. 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research: 49 abstr. PCN70, 16 May 2009. Available from: URL: http://www3.interscience.wiley.com
Rights and permissions
About this article
Cite this article
Bet on bevacizumab for metastatic colorectal cancer. Pharmacoecon. Outcomes News 579, 4 (2009). https://doi.org/10.2165/00151234-200905790-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905790-00005